- Home
- CRGX vs ORIC Comparison
CRGX vs ORIC Comparison
Compare CRGX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ORIC
- Stock Information
- Founded
- CRGX 2021
- ORIC 2014
- Country
- CRGX United States
- ORIC United States
- Employees
- CRGX N/A
- ORIC N/A
- Industry
- CRGX
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- ORIC Health Care
- Exchange
- CRGX Nasdaq
- ORIC Nasdaq
- Market Cap
- CRGX 190.0M
- ORIC 362.9M
- IPO Year
- CRGX 2023
- ORIC 2020
- Fundamental
- Price
- CRGX $4.57
- ORIC $11.03
- Analyst Decision
- CRGX Hold
- ORIC Strong Buy
- Analyst Count
- CRGX 7
- ORIC 9
- Target Price
- CRGX $5.33
- ORIC $18.29
- AVG Volume (30 Days)
- CRGX 2.2M
- ORIC 858.6K
- Earning Date
- CRGX 08-11-2025
- ORIC 08-11-2025
- Dividend Yield
- CRGX N/A
- ORIC N/A
- EPS Growth
- CRGX N/A
- ORIC N/A
- EPS
- CRGX N/A
- ORIC N/A
- Revenue
- CRGX N/A
- ORIC N/A
- Revenue This Year
- CRGX $57.81
- ORIC N/A
- Revenue Next Year
- CRGX N/A
- ORIC N/A
- P/E Ratio
- CRGX N/A
- ORIC N/A
- Revenue Growth
- CRGX N/A
- ORIC N/A
- 52 Week Low
- CRGX $3.00
- ORIC $3.90
- 52 Week High
- CRGX $25.45
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- CRGX 59.89
- ORIC 64.08
- Support Level
- CRGX $4.56
- ORIC $10.60
- Resistance Level
- CRGX $4.63
- ORIC $11.57
- Average True Range (ATR)
- CRGX 0.11
- ORIC 0.57
- MACD
- CRGX 0.02
- ORIC -0.08
- Stochastic Oscillator
- CRGX 74.24
- ORIC 72.32
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.